Hepasiri Granules, containing L-Ornithine L-Aspartate 10gm, is a hepatoprotective agent primarily indicated for the management of hepatic encephalopathy and other liver-related disorders. L-Ornithine L-Aspartate is an amino acid compound that facilitates ammonia detoxification by enhancing the urea cycle and glutamine synthesis in the liver and muscles, thereby reducing elevated blood ammonia levels commonly observed in hepatic insufficiency. This mechanism helps improve neuropsychiatric symptoms associated with hepatic encephalopathy and supports overall liver function. Hepasiri Granules are typically administered orally, allowing for rapid absorption and bioavailability. The formulation is beneficial as an adjunct therapy in chronic liver diseases such as cirrhosis, where ammonia accumulation contributes to cognitive impairment and muscle wasting. It is also used to manage hyperammonemia arising from other metabolic conditions. The safety profile of Hepasiri Granules is well-established, with minimal adverse effects reported when used as directed. Dose adjustments may be necessary in patients with renal impairment. Hepasiri Granules should be used under medical supervision, and patients are advised to adhere to prescribed dosages to optimize therapeutic outcomes while minimizing potential risks.